Pathology & Laboratory Medicine

Warning message

Selective filter "Related Faculty (field_biblio_faculty) (selective)" has limited the amount of total results. Please, review you query configuration.

Publications

Filter By Faculty

Filter by Principal Investigator

2024

Awad D, Cao PH, Pulliam TL, Spradlin M, Subramani E, Tellman TV, et al. Adipose Triglyceride Lipase Is a Therapeutic Target in Advanced Prostate Cancer That Promotes Metabolic Plasticity. Cancer Res. 2024;84(5):703-724.

Chen Y, Zhang L, Shi X, Han J, Chen J, Zhang X, et al. Characterization of the Nucleus Pulposus Progenitor Cells via Spatial Transcriptomics. Adv Sci (Weinh). 2024:e2303752.

Li J, Chin CR, Ying H-, Meydan C, Teater MR, Xia M, et al. Loss of CREBBP and KMT2D cooperate to accelerate lymphomagenesis and shape the lymphoma immune microenvironment. Nat Commun. 2024;15(1):2879.

Lee-Saxton YJ, Egan CE, Bratton BA, Thiesmeyer JW, Greenberg JA, Marshall TE, et al. Low Mitotic Activity in Papillary Thyroid Cancer: A Marker for Aggressive Features and Recurrence. J Clin Endocrinol Metab. 2024.

Khanjar B, Sejdiu Z, Mitre M, Mancebo S, Magro C, Harp J. Enfortumab vedotin toxic epidermal necrolysis-like blistering dermatosis: A case series and review of the literature. JAAD Case Rep. 2024;43:40-50.

Ntiri M, Nazarian A, Magro C, Alexis AF. Nodular (keloidal) scleroderma: A case series of 5 patients. JAAD Case Rep. 2024;49:135-139.

van Wyk AC, Lal P, J Ogunbiyi O, Kyokunda L, Hobenu F, Dial C, et al. Multinational, Multicenter Evaluation of Prostate Cancer Tissue in Sub-Saharan Africa: Challenges and Opportunities. JCO Glob Oncol. 2024;10:e2300403.

Chan AT, Maya TR, Park C, Tak K, Liberman N, Jain RH, et al. Incremental Utility of First-Pass Perfusion CMR for Prognostic Risk Stratification of Cancer-Associated Cardiac Masses. JACC Cardiovasc Imaging. 2024;17(2):128-145.

Pakula H, Omar M, Carelli R, Pederzoli F, Fanelli GN, Pannellini T, et al. Distinct mesenchymal cell states mediate prostate cancer progression. Nat Commun. 2024;15(1):363.

Rowdo FP, Xiao G, Khramtsova GF, Nguyen J, Martini R, Stonaker B, et al. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer Lett. 2024;584:216608.